{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T08:54:39Z","timestamp":1792313679670,"version":"4.4.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.nefro.2020.10.001","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T06:00:42Z","timestamp":1608789642000},"page":"258-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Bloqueantes del receptor mineralcorticoide en la enfermedad renal cr\u00f3nica"],"prefix":"10.1016","volume":"41","author":[{"given":"Sara","family":"Erraez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"L\u00f3pez-Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"G\u00f3mez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2020.10.001_bib0755","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0760","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0765","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal Insufficiency study group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0770","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0775","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2020.10.001_bib0780","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0785","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"Randomized aldactone evaluation study investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0790","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0795","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0800","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02155834","article-title":"Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism","volume":"9","author":"Simpson","year":"1953","journal-title":"Experientia."},{"key":"10.1016\/j.nefro.2020.10.001_bib0805","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0810","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1530\/JME-16-0025","article-title":"Adipocytes, aldosterone and obesity-related hypertension","volume":"57","author":"Dinh Cat","year":"2016","journal-title":"J Mol Endocrinol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-01882-2","article-title":"Involvement of vascular aldosterone synthase In phosphate-induced osteogenic transformation of vascular smooth muscle cells","volume":"7","author":"Alesutan","year":"2017","journal-title":"Sci Rep."},{"key":"10.1016\/j.nefro.2020.10.001_bib0820","first-page":"105","article-title":"Regulation of aldosterone secretion: Current concepts and newer aspects","volume":"7","author":"Bravo","year":"1977","journal-title":"Adv Nephrol Necker Hosp."},{"key":"10.1016\/j.nefro.2020.10.001_bib0825","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2015010093","article-title":"Antiaging gene Klotho regulates CYP11B2 expression and aldosterone synthesis","volume":"27","author":"Zhou","year":"2016","journal-title":"Am J Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0830","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science."},{"key":"10.1016\/j.nefro.2020.10.001_bib0835","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1677\/JME-09-0031","article-title":"The mineralocorticoid receptor and its coregulators","volume":"43","author":"Yang","year":"2009","journal-title":"J Mol Endocrinol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0840","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","article-title":"Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability","volume":"45","author":"Nishiyama","year":"2005","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib0845","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: Rroles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib0850","first-page":"41","article-title":"Identification and role of aldosterone receptors in the cardiovascular system","volume":"61","author":"Lomb\u00e8s","year":"2000","journal-title":"Ann Endocrinol (Paris)."},{"key":"10.1016\/j.nefro.2020.10.001_bib0855","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","article-title":"Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion","volume":"102","author":"Caprio","year":"2008","journal-title":"Circ Res."},{"key":"10.1016\/j.nefro.2020.10.001_bib0860","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1096\/fj.06-7970com","article-title":"Pivotal role of the mineralocorticoid receptor in corticosteroid induced adipogenesis","volume":"21","author":"Caprio","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.nefro.2020.10.001_bib0865","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tins.2007.10.005","article-title":"The coming out of the brain mineralocorticoid receptor","volume":"3","author":"Jo\u00ebls","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.nefro.2020.10.001_bib0875","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/JME-15-0318","article-title":"Mineralocorticoid regulation of cell function: The role of rapid signalling and gene transcription pathways","volume":"58","author":"Ong","year":"2017","journal-title":"Mol Endocrino."},{"key":"10.1016\/j.nefro.2020.10.001_bib0880","doi-asserted-by":"crossref","first-page":"T107","DOI":"10.1530\/JOE-16-0659","article-title":"30 years of the mineralocorticoid receptor: Nongenomic effects via the mineralocorticoid receptor","volume":"234","author":"Ruhs","year":"2017","journal-title":"J Endocrinol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0885","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nrneph.2012.282","article-title":"Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease","volume":"9","author":"Nagase","year":"2013","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0890","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomy-ocytes: Role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib0895","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0900","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000358758","article-title":"Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease","volume":"126","author":"Yoshida","year":"2014","journal-title":"Nephron Exp Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0905","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1172\/JCI43124","article-title":"Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway","volume":"121","author":"Shibata","year":"2011","journal-title":"J Clin Invest."},{"key":"10.1016\/j.nefro.2020.10.001_bib0910","doi-asserted-by":"crossref","first-page":"T35","DOI":"10.1530\/JOE-16-0669","article-title":"Mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron","volume":"234","author":"Shibata","year":"2017","journal-title":"J Endocrinol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0915","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/HYPERTENSIONAHA.116.08519","article-title":"Hypokalemia and Pendrin induction by aldosterone","volume":"69","author":"Xu","year":"2017","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib0920","doi-asserted-by":"crossref","first-page":"C1251","DOI":"10.1152\/ajpcell.00076.2011","article-title":"Aldosterone stimulates vacuolar H(+)-ATPase activity in renal acid-secretory intercalated cells mainly via a protein kinase C-dependent pathway","volume":"301","author":"Winter","year":"2011","journal-title":"Am J Physiol Cell Physiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0925","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1172\/JCI38323","article-title":"Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway","volume":"119","author":"Rozansky","year":"2009","journal-title":"J Clin Invest."},{"key":"10.1016\/j.nefro.2020.10.001_bib0930","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.111.173195","article-title":"Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors","volume":"59","author":"Fu","year":"2012","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib0935","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/HYPERTENSIONAHA.113.01846","article-title":"Connecting tubule glomerular feedback in hypertension","volume":"62","author":"Wang","year":"2013","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib0940","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11906-019-0911-5","article-title":"A novel mechanism of renal microcirculation regulation: Connecting tubule-glomerular feedback","volume":"21","author":"Romero","year":"2019","journal-title":"Curr Hypertens Rep."},{"key":"10.1016\/j.nefro.2020.10.001_bib0945","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","article-title":"The role of the mineralocorticoid receptor in the vasculature","volume":"234","author":"DuPont","year":"2017","journal-title":"J Endocrinol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0950","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.118.11339","article-title":"Epitelial sodium channel in aldosterone-induced endothelium stiffness and aortic dysfunction","volume":"72","author":"Jia","year":"2018","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib0955","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1093\/ndt\/gfs014","article-title":"Recovery from ischemic acute injury by spironolactone administration","volume":"27","author":"S\u00e1nchez-Pozos","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2020.10.001_bib0960","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.2015.312","article-title":"Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration","volume":"89","author":"Amador","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib0965","doi-asserted-by":"crossref","first-page":"F723","DOI":"10.1152\/ajprenal.00480.2006","article-title":"Aldosterone induces epithelial-mesenchy-mal transition via ROS of mitochondrial\u00a0origin","volume":"293","author":"Zhang","year":"2007","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib0970","doi-asserted-by":"crossref","first-page":"17479","DOI":"10.18632\/oncotarget.8243","article-title":"Mitochondrial \u2014reactive oxygen species mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury","volume":"7","author":"Ding","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.nefro.2020.10.001_bib0975","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1214243","article-title":"Acute kidney injury and chronic kidney disease as interconnected syndromes","volume":"371","author":"Chawla","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib0980","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralcorticoid receptor controls inflammatory and fibro-tic responses after renal injury via macrophage interleukin 4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib0985","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2012.352","article-title":"Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury","volume":"83","author":"Barrera-Chimal","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib0990","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.kint.2019.05.015","article-title":"From podocyte biology to novel cures for glomerular disease","volume":"96","author":"Torban","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib0995","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","article-title":"Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk1","volume":"49","author":"Shibata","year":"2007","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib1000","doi-asserted-by":"crossref","first-page":"F556","DOI":"10.1152\/ajprenal.00332.2016","article-title":"NLRP3 inflam-masome activation contributes to aldosterone induced podocyte injury","volume":"312","author":"Bai","year":"2017","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1681\/ASN.2007050531","article-title":"Aldosterone-stimulated SGK1 activity mediates profibrotic signaling in the mesangium","volume":"19","author":"Terada","year":"2008","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1010","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1681\/ASN.2012111094","article-title":"Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease","volume":"25","author":"Huang","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1015","doi-asserted-by":"crossref","first-page":"H357","DOI":"10.1152\/ajpheart.00081.2019","article-title":"Aldosterone impairs coronary adenosine-mediated vasodilation via reduced functional expression of Ca2-activated K-channels","volume":"317","author":"Khan","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1020","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1681\/ASN.2015030301","article-title":"Prognostic value of coronary flow reserve in patients with dialysis-de-pendent ESRD","volume":"27","author":"Shah","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1025","doi-asserted-by":"crossref","first-page":"F967","DOI":"10.1152\/ajprenal.00669.2014","article-title":"Spironolactone ameliorates arteria medial calcification in uremic rats medial calcification: The role of mineralocorticoid receptor signaling in vascular calcification","volume":"309","author":"Tsatsumoto","year":"2015","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/cs0950687","article-title":"Aldosterone blunts the baroreflex response in man","volume":"95","author":"Yee","year":"1998","journal-title":"Clin Sci (Lond)."},{"key":"10.1016\/j.nefro.2020.10.001_bib1035","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/HYPERTENSIONAHA.109.147058","article-title":"Impact of Aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension","volume":"55","author":"Wray","year":"2010","journal-title":"Hypertension."},{"issue":"10008","key":"10.1016\/j.nefro.2020.10.001_bib1040","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2020.10.001_bib1045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","article-title":"Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial","volume":"54","author":"Edwards","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1050","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1681\/ASN.2014050450","article-title":"Mediation analysis of aortic stiffness and renal microvascular function","volume":"26","author":"Woodard","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hen\u00e9","year":"1982","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib1060","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11906-011-0202-2","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"13","author":"Volk","year":"2011","journal-title":"Curr Hypertens Rep."},{"key":"10.1016\/j.nefro.2020.10.001_bib1065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s12882-017-0789-x","article-title":"Renoprotective RAAS inhibition\u00a0does not affect the association between worse renal function and higher plasma aldosterone levels","volume":"18","author":"Gant","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1070","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2010121251","article-title":"Cross Talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease","volume":"22","author":"de Borst","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1075","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expresi\u00f3n of mineral-corticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation."},{"key":"10.1016\/j.nefro.2020.10.001_bib1080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1085","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renopro-tection of optimal antiproteinuric doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1090","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ."},{"key":"10.1016\/j.nefro.2020.10.001_bib1095","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.amjhyper.2007.09.001","article-title":"Aldosterone breakthrough during\u00a0angiotensin ii receptor blockade in hypertensive patients with diabetes mellitus","volume":"20","author":"Yoneda","year":"2007","journal-title":"Am J Hypertens."},{"key":"10.1016\/j.nefro.2020.10.001_bib1105","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia."},{"issue":"6B","key":"10.1016\/j.nefro.2020.10.001_bib1110","first-page":"24S","article-title":"Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists","volume":"87","author":"Johnston","year":"1989","journal-title":"Am J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4330\/wjc.v9.i3.200","article-title":"Angiotensin receptor blocker drugs and inhi-bition of adrenal beta-arrestin-1-dependent aldosterone production: Implications for heart failure therapy","volume":"9","author":"Lymperopoulos","year":"2017","journal-title":"World J Cardiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1125","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib1130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ndt\/gfs429","article-title":"Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases","volume":"28","author":"Morales","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2020.10.001_bib1135","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1140","first-page":"CD007004","article-title":"Aldosterone anta-gonists for preventing the progression of chronic kidney disease","volume":"29","author":"Bolignano","year":"2014","journal-title":"Cochrane Data-base Syst Rev."},{"key":"10.1016\/j.nefro.2020.10.001_bib1145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralcorticoid receptor antagonist on proteinuria and progression of chronic kidney disease","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1150","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/jcm7110459","article-title":"Long term effects of spironolactone on kidney function and hyperkalemia-associated hospitalization in patients with chronic kidney disease","volume":"7","author":"Yang","year":"2018","journal-title":"J Clin Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1155","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2020.10.001_bib1160","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","article-title":"Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease","volume":"32","author":"Mima","year":"2018","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.nefro.2020.10.001_bib1165","doi-asserted-by":"crossref","first-page":"F1026","DOI":"10.1152\/ajprenal.00605.2014","article-title":"Tubuloglomerular and connecting tubuloglomerular feedback during inhibition of various Na transporters in the nephron","volume":"308","author":"Wang","year":"2015","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1745-6215-15-160","volume":"15","author":"Hill","year":"2014","journal-title":"Trials."},{"key":"10.1016\/j.nefro.2020.10.001_bib1175","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Pre-venting microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1180","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Eng J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1185","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2020.10.001_bib1190","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"Irbesartan in patients with type 2 diabetes and microalbuminuria. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1195","first-page":"4309","article-title":"Renal outcomes with aliskiren in patients with type 2 diabetes: A prespecified secondary analysis of the ALTITUDE randomised controlled trial","author":"Heerspink","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1200","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropa-thy","volume":"358","author":"Parving","year":"2008","journal-title":"N Eng J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1205","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1210","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.nefro.2020.10.001_bib1215","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011303","article-title":"Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1220","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Efffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1225","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angio-tensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1230","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4239\/wjd.v7.i5.101","article-title":"Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management","volume":"7","author":"Sousa","year":"2016","journal-title":"World J Diabetes."},{"key":"10.1016\/j.nefro.2020.10.001_bib1235","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/ajkd.2000.16192","article-title":"Angiotensin II and its receptors in the diabetic kidney","volume":"36","author":"Burns","year":"2000","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2020.10.001_bib1240","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib1245","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib1250","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/ndt\/gfq750","article-title":"Spironolactone inhibits hyperglycemia induced podocyte injury by attenuating ROS production","volume":"26","author":"Toyonaga","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2020.10.001_bib1255","doi-asserted-by":"crossref","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","article-title":"Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions","volume":"297","author":"Lee","year":"2009","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1260","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.freeradbiomed.2005.03.031","article-title":"Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement","volume":"39","author":"Tsubouchi","year":"2005","journal-title":"Free Radic Biol Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1265","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jdi.12629","article-title":"Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy","volume":"8","author":"Sun","year":"2017","journal-title":"J Diabetes Investig."},{"key":"10.1016\/j.nefro.2020.10.001_bib1270","first-page":"e13413","article-title":"Efficacy and safety of mineralcorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: A metaanalysis","author":"Zuo","year":"2019","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.nefro.2020.10.001_bib1275","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial inter-vention in patients with type 2 diabetes mellitus and microalbuminuria: Rhe Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2020.10.001_bib1280","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Pre-venting microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1285","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1038\/s41598-019-49525-y","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Bae","year":"2019","journal-title":"Sci Rep."},{"key":"10.1016\/j.nefro.2020.10.001_bib1290","unstructured":"Clinical Trials Gov. Proteomic prediction and renin angiotensin aldosterone system inhibition prevention of early diabetic nephropathy in type 2 diabetic patients with normoalbuminuria (PRIORITY) [Fecha de consulta: 17 Ago 2020] NCT02040441."},{"key":"10.1016\/j.nefro.2020.10.001_bib1295","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1300","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1305","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomized trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1310","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-9343(03)00293-6","article-title":"Aldosterone blockade and vascular calcification in hemodialysis patients","volume":"115","author":"Nitta","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.nefro.2020.10.001_bib1315","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1053\/j.ajkd.2014.01.426","article-title":"Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: A randomized controlled trial","volume":"63","author":"Vazquez-Rangel","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2020.10.001_bib1320","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/ehs361","article-title":"Aldosterone and cortisol affect the risk of sudden cardiac death in haemodia-lysis patients","volume":"34","author":"Drechsler","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefro.2020.10.001_bib1325","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1330","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2016.04.011","article-title":"The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: A systematic review and meta-analysis","volume":"68","author":"Quach","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2020.10.001_bib1335","first-page":"1925243","article-title":"Aldosterone antagonists reduce the risk of cardiovascular mortality in dialysis patients: A meta-analysis","volume":"2019","author":"Li","year":"2019","journal-title":"Evid Based Complement Alternat Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1340","unstructured":"Aldosterone antagonist chronic hemodialysis interventional survival trial (ALCHEMIST) NCT Clinical trial.gov. [Fecha de consulta: 17 Ago 2020] 01848639."},{"key":"10.1016\/j.nefro.2020.10.001_bib1345","unstructured":"Clinical Trial Gov Aldosterone blockade for health Improvement evaluation in end-stage renal disease (ACHIEVE) [Fecha de consulta: 17 Ago 2020] NCT03020303."},{"key":"10.1016\/j.nefro.2020.10.001_bib1350","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.nefro.2020.10.001_bib1355","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.ajkd.2017.12.006","article-title":"Management of heart failure in advancing CKD: Core curriculum 2018","volume":"72","author":"House","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2020.10.001_bib1360","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1365","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: Insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1370","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.nefro.2020.10.001_bib1375","unstructured":"EudraCT 2015-68-17.FINESSE-HF. A multicenter randomized double-dummy, parallel-group, active-controlled study to evaluate the efficacy, safety of finerenone compared to eplerenone on morbidity, mortality in patients with chronic heart failure, reduced ejection fraction after recent heart failure descompensation, additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or both."},{"key":"10.1016\/j.nefro.2020.10.001_bib1380","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","article-title":"Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: The widening gap between manda-ted\u00a0treatment guidelines and the real-world clinical arena","volume":"6","author":"Ebstein","year":"2016","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.nefro.2020.10.001_bib1385","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure. Chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1390","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/path.1750","article-title":"Enhanced large intestinal potassium permeability in end-stage renal disease","volume":"206","author":"Mathialahan","year":"2005","journal-title":"J Pathol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1395","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: Current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2020.10.001_bib1400","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1113\/jphysiol.2008.156968","article-title":"Aldosterone increases KCa1.1(BK) channel mediated colonic K+secretion","volume":"586","author":"S\u00f8rensen","year":"2008","journal-title":"J Physiol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1405","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J."},{"issue":"11 Suppl","key":"10.1016\/j.nefro.2020.10.001_bib1410","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.nefro.2020.10.001_bib1415","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1420","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2020.10.001_bib1425","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2020.10.001_bib1430","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralo-corticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.nefro.2020.10.001_bib1435","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1440","unstructured":"ClinicalTrial.Gov. A study to asses the pharmacodynamic effect of single doses of AZD9977 in healthy male subjects. [Fecha de consulta: 17 Ago 2020] NCT02532998."},{"key":"10.1016\/j.nefro.2020.10.001_bib1445","unstructured":"ClinicalTrial.Gov. A study to assess the safety, tolerability and pharma-cokinetics of AZD9977 after single ascending doses to healthy males. [Fecha de consulta: 17 Ago 2020] NCT02484729."},{"key":"10.1016\/j.nefro.2020.10.001_bib1450","unstructured":"ClinicalTrial.Gov. Study in HFpEF patients to compare the effect of AZD9977 and spironolactone on serum potassium. [Fecha de consulta: 17 Ago 2020] NCT03682497."},{"key":"10.1016\/j.nefro.2020.10.001_bib1455","unstructured":"ClinicalTrial.Gov. Phase 2b Study of KBP-5074 in subjects with uncon-trolled hypertension and advanced chronic kidney disease. [Fecha de consulta: 17 Ago 2020] NCT03574363."},{"key":"10.1016\/j.nefro.2020.10.001_bib1460","unstructured":"ClinicalTrials.Gov. Efficacy and safety of MT-3995 in patients with diabetic nephropathy. NCT02517320."},{"key":"10.1016\/j.nefro.2020.10.001_bib1465","doi-asserted-by":"crossref","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51-58 doi: 10.1161\/HYPERTENSION AHA.119.13569.","DOI":"10.1161\/HYPERTENSIONAHA.119.13569"},{"key":"10.1016\/j.nefro.2020.10.001_bib1470","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by reduction in oxidative stress","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1475","doi-asserted-by":"crossref","first-page":"e0184888","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralcorticoid receptor antagonist finereno-ne attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.nefro.2020.10.001_bib1480","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefro.2020.10.001_bib1485","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.nefro.2020.10.001_bib1490","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA."},{"key":"10.1016\/j.nefro.2020.10.001_bib1495","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefro.2020.10.001_bib1500","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169952030165X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169952030165X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:56:37Z","timestamp":1759323397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021169952030165X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":150,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S021169952030165X"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2020.10.001","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bloqueantes del receptor mineralcorticoide en la enfermedad renal cr\u00f3nica","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2020.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}